12/20
09:41 pm
dbvt
Why DBV Technologies (ENXTPA:DBV) Is Up 11.8% After Positive Phase 3 Viaskin Peanut Patch Data [Yahoo! Finance]
High
Report
Why DBV Technologies (ENXTPA:DBV) Is Up 11.8% After Positive Phase 3 Viaskin Peanut Patch Data [Yahoo! Finance]
12/18
10:04 am
dbvt
DBV Technologies (NASDAQ:DBVT) was given a new $40.00 price target on by analysts at HC Wainwright.
Medium
Report
DBV Technologies (NASDAQ:DBVT) was given a new $40.00 price target on by analysts at HC Wainwright.
12/17
10:57 am
dbvt
DBV Technologies (NASDAQ:DBVT) was given a new $48.00 price target on by analysts at Cantor Fitzgerald.
Medium
Report
DBV Technologies (NASDAQ:DBVT) was given a new $48.00 price target on by analysts at Cantor Fitzgerald.
12/17
08:05 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
12/17
07:06 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
06:04 am
dbvt
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
Medium
Report
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
12/17
06:02 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/16
10:11 pm
dbvt
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
High
Report
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
12/16
04:39 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
12/16
04:05 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
12/16
05:43 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
12/15
07:20 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/14
07:02 pm
dbvt
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
12/11
01:47 am
dbvt
DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally [Seeking Alpha]
Medium
Report
DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally [Seeking Alpha]
12/4
07:18 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Guggenheim to a "strong-buy" rating. They now have a $35.00 price target on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Guggenheim to a "strong-buy" rating. They now have a $35.00 price target on the stock.
12/3
07:02 am
dbvt
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/2
04:00 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
12/2
03:41 pm
dbvt
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:05 pm
dbvt
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
12:01 am
dbvt
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
Medium
Report
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
11/11
11:50 pm
dbvt
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Medium
Report
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
11/10
01:20 pm
dbvt
Food Allergy Market Valued at USD 3 Billion across the 7MM, Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Food Allergy Market Valued at USD 3 Billion across the 7MM, Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight [Yahoo! Finance]
11/4
04:30 pm
dbvt
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
11/3
04:30 pm
dbvt
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Low
Report
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
11/3
04:25 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025